We offer innovative NGS-based solutions for the quality control of biologics to improve the quality of life of patients by accelerating commercial availability of biologics and assisting with the rapid diagnosis of infectious diseases

About Us

About Us

We offer innovative NGS-based solutions for the quality control of biologics to improve the quality of life of patients by accelerating commercial availability of biologics and assisting with the rapid diagnosis of infectious diseases

WHAT WE DO

PathoQuest, a spin-out of Institut Pasteur Paris, is a genomic expert company offering a game-changing next-generation sequencing (NGS) approach for microbiology testing.

The NGS-based technology the company developed is used for:

  • The quality control (QC) testing of biologicals (e.g., ATMP, vaccines, antibodies), enabling rapid and robust analysis from non-regulated to GMP level

PathoQuest’s technology leverages the company’s proprietary sample preparation protocols, which are applicable to several types of biological samples, proprietary internally-curated pathogen genome databases, and automated analysis pipelines.

OUR MISSION & VISION

PathoQuest develops proprietary metagenomic-based tests and software tools that are designed to improve the detection and identification of pathogens and enable the safe and high-quality production of biologics.

 

To become a worldwide leader in the quality control for biologics and bioproduction samples, and to accelerate the time to market for innovative drugs

| HOW WE DO IT

Projects

Customers

Employees

Sites

| OUR PEOPLE

Our Expertise

Recognized experts embody PathoQuest in infectious diseases, microbiology, and molecular diagnostics. They assist you every step of the way from our R&D efforts to the implementation of your NGS-based QC strategy.

Management Team

PathoQuest’s management team has significant experience and expertise in in-vitro diagnostics, for the development, validation, and commercialization of metagenomic solutions for the identification of pathogens.  

Board of Directors

PathoQuest is led by a board of directors who are seasoned leaders in their respective fields of business. Together, the members of the board of directors help to develop policies and strategies which are implemented by PathoQuest’s executive team.

OUR HISTORY

2010 2010
2014 2014
2015 2015
2016 2016
2018 2018
2019 2019
Sep. 2020 Sep. 2020
Nov. 2020 Nov. 2020
Dec. 2020 Dec. 2020
Jan. 2021 Jan. 2021
Oct.2021 Oct.2021
Nov.2021 Nov.2021
Nov.2021 Nov.2021

2010

Company based in Paris. Spun out of Institut Pasteur

2014

Member of AVDTIG Task Force

2015

2 Distinct Business Units

  • Biologics Genomic Testing
  • Clinical Diagnostics of infectious diseases

2016

Partnership for biologics testing with a global leader

  • Strategic agreement with Charles River
  • Validation of technology

 

2018

Winner of the Frost & Sullivan’s Product Line Strategy Leadership Award in the infectious disease diagnostics market

2019

Kurma, Idinvest historical investors

  • 8M€ financing in Q2

Sep. 2020

Pharmaceutical Establishment

  • from the French Agence Nationale de Sécurité du Médicament (ANSM) for the biological drug testing activities

Nov. 2020

Announce of the future U.S. lab

  • Subsidary PathoQuest, Inc. genomic testing laboratory in Wayne, PA.

Dec. 2020

PM’up Grant

  • Support from the Île-de-France region (France) as part of the PM’up Relance Industrie program

Jan. 2021

Member of CAACB

  • PathoQuest signed an agreement with the Massachusetts Institute of Technology (MIT) to join the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) as an associate member

Oct.2021

PIA 4

  • €0.85M grant from the French Investment Program for the Future (Programme d’Investissement d’Avenir – PIA 4)

Nov.2021

Series B financing round led by SHS Capital

  • €15 million funding round led by new investors, SHS Capital (Germany), followed by Turenne Capital/SHAM (France) and a US Family Office to reinforce the support from existing shareholders.

Nov.2021

GMP Certification

  • PathoQuest has obtained a Good Manufacturing Practices (GMP) certificate for its quality control testing activities at its French-based facilities in Paris (France), following a recent inspection by the French National Agency for the Safety of Medicine and Health Products (ANSM)
w

Let’s Start Something New

Welcome to PathoQuest!

9 + 2 =

EnglishFrenchGermanSpanish